Volume 15, Issue 1, Pages S20-S28 (January 2012)

Slides:



Advertisements
Similar presentations
A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Advertisements

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.
Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,
Volume 14, Issue 8, Pages (December 2011)
Volume 18, Issue 4, Pages (June 2015)
Volume 18, Issue 5, Pages (July 2015)
Volume 18, Issue 2, Pages (March 2015)
Mapping the COPD Assessment Test onto EQ-5D
Volume 15, Issue 2, Pages (March 2012)
Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Volume 17, Issue 2, Pages (March 2014)
Volume 14, Issue 1, Pages (January 2011)
Volume 18, Issue 4, Pages (June 2015)
Volume 18, Issue 8, Pages (December 2015)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 14, Issue 4, Pages (June 2011)
Volume 15, Issue 2, Pages (March 2012)
Volume 15, Issue 6, Pages (September 2012)
Volume 14, Issue 8, Pages (December 2011)
Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores 
Volume 15, Issue 1, Pages (January 2012)
Volume 19, Issue 5, Pages (July 2016)
Volume 15, Issue 2, Pages (March 2012)
Volume 17, Issue 2, Pages (March 2014)
Examining the Value of Menopausal Symptom Relief Among US Women
Volume 17, Issue 2, Pages (March 2014)
Value in Health Regional Issues
Value in Health Regional Issues
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil  Eduardo Gehling Bertoldi, MD, MSc, Milena S.
Value in Health Regional Issues
Value in Health Regional Issues
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Value in Health Regional Issues
Value in Health Regional Issues
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Value in Health Regional Issues
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Presentation transcript:

Volume 15, Issue 1, Pages S20-S28 (January 2012) Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis  Pritaporn Kingkaew, BPharm, MSc, Usawadee Maleewong, BPharm, PhD, Chardpraorn Ngarmukos, MD, Yot Teerawattananon, MD, PhD  Value in Health  Volume 15, Issue 1, Pages S20-S28 (January 2012) DOI: 10.1016/j.jval.2011.11.015 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Decision tree illustrating two systematic screening compare to ‘Null’ scenario, followed by Markov model representing a disease partway once postmenopausal women are diagnosed with osteoporosis. Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Incremental cost-effectiveness plane illustrating two selected age group, 50 years and 80 years. Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Incremental cost-effectiveness ratios of providing different universal screening strategies at various age groups. Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cost-effectiveness acceptability curves of treatment options (A) in patients who start the treatments for primary prevention of osteoporotic fractures at the ages of 50 and 80 (B) in patients who start the treatments for secondary prevention of osteoporotic fractures at the ages of 50 and 80. Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Cost-effectiveness acceptability curves of screening modalities for osteoporosis in postmenopausal women ages 50 and 80. If positive results confirm with DXA, alendronate will be given to osteoporosis patients for primary prevention of osteoporotic fractures. Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 6 One-way sensitivity analysis of adjusting drug compliance of all drugs and discontinuation of bisphosphonate (Primary prevention of osteoporotic fractures). Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 7 One-way sensitivity analysis of adjusting drug compliance of all drugs and discontinuation of bisphosphonate (Secondary prevention of osteoporotic fractures). Value in Health 2012 15, S20-S28DOI: (10.1016/j.jval.2011.11.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.